The Biomarker Temporal Sequence Hypothesis proposes that Alzheimer's disease follows a predictable sequence of biomarker abnormalities, with specific biomarkers becoming abnormal at predictable stages of disease progression. This ordering provides a framework for disease staging, early diagnosis, and clinical trial design.
This hypothesis was substantially developed through computational modeling studies, particularly the 2023 study by Wijeratne, Eshaghi, and colleagues on the Temporal Event-Based Model (TEBM), which demonstrated that biomarker events occur in a specific temporal sequence in progressive neurodegenerative diseases[1].
In Alzheimer's disease, biomarker events occur in a specific temporal sequence:
The Temporal Event-Based Model (TEBM) can:
In amyloid-positive (CSF Aβ₁₋₄₂ < 192 pg/ml) or APOE-positive subjects, CSF biomarkers become abnormal in the sequence:
Biomarker changes are monotonic throughout disease progression—they consistently increase or decrease as disease advances, without oscillating[1].
Established - The general sequence (Aβ → tau → neurodegeneration → cognitive decline) is well-established. Computational models can accurately estimate this sequence. This framework is widely used for disease staging and clinical trial enrichment.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 1 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 75% |
Overall Confidence: 61%